Sources: Otsuka prepares to go public

Japan's Otsuka Pharmaceutical plans to go public with a market capitalization of around $11 billion, reports Reuters, quoting sources close to the company. That will leave Otsuka behind Takeda, Astellas, and Daiichi Sankyo and even with Eisai. The Japanese pharma companies have been playing a growing role partnering with U.S. biotech companies in recent years. Report

Suggested Articles

After delivering a "positive surprise" in December, Biogen is painting a fuller picture of its lupus drug.

A new CRISPR technique neutralizes SARS-CoV-2 by scrambling the virus' genetic code. It could prove useful for fighting other viruses, like influenza.

The deal, which follows a bidding war with AcelRx, gives Melinta another approved antibiotic and potentially complementary R&D expertise.